What Is Half-Life?
Half-life (t½) is the time required for the concentration of a compound in a biological system to decrease by 50% from its initial value. It is one of the most important pharmacokinetic parameters in research protocol design — determining how frequently a compound must be administered to maintain a target exposure level, how long biological effects persist after a single administration, and how long the compound remains detectable in biological samples. Understanding half-life is essential for designing research protocols that achieve consistent, reproducible compound exposures across the duration of a study.
Why Peptides Generally Have Short Half-Lives
Proteolytic Degradation
The primary reason most native peptides have short plasma half-lives is proteolytic degradation — the enzymatic cleavage of peptide bonds by proteases circulating in plasma, present in tissues, and lining the gastrointestinal tract. Humans produce hundreds of proteases with overlapping substrate specificities, and most native peptide sequences contain cleavage sites for multiple proteases simultaneously. Once a critical peptide bond is cleaved, the resulting fragments typically lose biological activity and are rapidly further degraded to amino acids and recycled. Endogenous peptide hormones such as native GLP-1 (~2 minutes), native GHRH (~7 minutes), and native amylin (~15 minutes) have very short half-lives precisely because rapid clearance is part of their normal physiological regulation.
Renal Filtration
Small peptides (generally under ~6,000 Da) can be filtered through the glomerular basement membrane of the kidney and excreted in urine. Peptides that are not bound to plasma proteins and are small enough to pass through the glomerular filter have a renal clearance component in addition to proteolytic degradation, shortening their effective half-life further.
Receptor-Mediated Internalization
Peptides that bind cell surface receptors can be internalized along with their receptor through endocytosis — removing them from circulation and targeting them for lysosomal degradation. This receptor-mediated clearance mechanism is concentration-dependent and receptor expression-dependent, contributing to the overall clearance of receptor-binding peptides.
How Research Peptides Are Engineered for Extended Half-Life
A major focus of pharmaceutical peptide chemistry has been extending peptide half-life — making compounds suitable for practical research and therapeutic applications requiring exposures lasting hours to days rather than minutes. Several engineering strategies are used across the research peptide catalog.
Fatty Acid Acylation and Albumin Binding
The most widely used half-life extension strategy in the GLP-1 class is fatty acid acylation — attaching a fatty acid chain (C16, C18, C20) to the peptide through a hydrophilic linker. The fatty acid enables reversible, non-covalent binding to serum albumin — the most abundant plasma protein, with a half-life of approximately 19 days. Albumin-bound peptides are too large to be renally filtered, are protected from some proteases by their bound conformation, and slowly release as free peptide over time. This strategy enables once-weekly dosing for semaglutide (~7-day half-life), tirzepatide (~5-day), retatrutide (~6-day), and cagrilintide (~7-day). The same principle produces the extended half-life of CJC-1295 with DAC.
DPP-IV Resistance Through Amino Acid Substitution
Dipeptidyl peptidase IV (DPP-IV) rapidly cleaves the N-terminal dipeptide from peptides with a penultimate proline or alanine at position 2 — including native GLP-1, GIP, and GHRH. Substituting a DPP-IV-resistant amino acid at position 2 dramatically extends half-life by removing this major clearance pathway. CJC-1295 uses this strategy to extend its half-life to approximately 30 minutes compared to sermorelin‘s ~7 minutes.
D-Amino Acid Substitution
Natural proteases are stereospecific — they cleave L-amino acid peptide bonds with high efficiency but have dramatically reduced activity against D-amino acid bonds. Incorporating D-amino acids at protease-susceptible positions dramatically reduces proteolytic degradation. SS-31 is constructed entirely from D-amino acids. FOXO4-DRI uses the D-retro-inverso configuration specifically to achieve sufficient in vivo half-life for tissue penetration — the D-amino acid backbone is essential to its in vivo efficacy.
Cyclization
Cyclizing a peptide removes the free termini that are primary targets for exopeptidases and constrains the peptide in a conformation that may be less accessible to endopeptidases. Melanotan 2 is a cyclic α-MSH analogue — its lactam bridge cyclization contributes to its enhanced metabolic stability. PT-141 is similarly cyclic, contributing to its practical in vivo half-life.
Stabilizing Amino Acid Substitutions
Replacing oxidation-prone residues with stable analogues eliminates chemical degradation pathways that contribute to effective half-life loss. Melanotan 1 replaces the methionine at position 4 of native α-MSH with norleucine — eliminating the methionine oxidation pathway that would otherwise rapidly inactivate the peptide and extend its functional half-life accordingly. Tesamorelin uses a trans-3-hexenoic acid modification for stability.
Half-Life in the AminoForge Research Catalog: Quick Reference
Very short (~minutes): Sermorelin (~7 min, DPP-IV sensitive), small peptide bioregulators (Epitalon, Pinealon, Cartalax — rapidly cleared)
Short-to-moderate (~30 min to hours): CJC-1295 No DAC (~30 min), Tesamorelin (~26 min), Ipamorelin (~2 hours), BPC-157 (~4 hours in preclinical models), TB-500, GHK-Cu
Extended (days to week+): Semaglutide (~7 days), Cagrilintide (~7 days), Retatrutide (~6 days), Tirzepatide (~5 days), CJC-1295 With DAC (several days)
For further reading on peptide pharmacokinetics and half-life engineering see: Strategies for extending peptide half-life in drug development (PubMed).
Browse the full AminoForge research peptide catalog at aminoforge.vegas/shop — 40+ compounds, ≥99% purity, COA verified, USA manufactured, ships within 48 hours.
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.